Display options
Cite
Zhong P, Song L, Gao M, et al. Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis. Evid Based Complement Alternat Med. 2020;2020:2957567doi: 10.1155/2020/2957567.
Zhong, P., Song, L., Gao, M., Wang, X., Tan, W., Lu, H., Lan, Q., Zhao, Z., & Zhao, W. (2020). Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis. Evidence-based complementary and alternative medicine : eCAM, 20202957567. https://doi.org/10.1155/2020/2957567
Zhong, Peicheng, et al. "Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis." Evidence-based complementary and alternative medicine : eCAM vol. 2020 (2020): 2957567. doi: https://doi.org/10.1155/2020/2957567
Zhong P, Song L, Gao M, Wang X, Tan W, Lu H, Lan Q, Zhao Z, Zhao W. Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis. Evid Based Complement Alternat Med. 2020 Jul 29;2020:2957567. doi: 10.1155/2020/2957567. eCollection 2020. PMID: 32802121; PMCID: PMC7414372.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2020 Jul 29;2020:2957567. doi: 10.1155/2020/2957567. eCollection 2020.

Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Gegen Qinlian Decoction for Rotavirus Enteritis.

Evidence-based complementary and alternative medicine : eCAM

Peicheng Zhong, Lijun Song, Mengyue Gao, Xiaotong Wang, Wenpan Tan, Huanqian Lu, Qian Lan, Zuyi Zhao, Wenchang Zhao

Affiliations

  1. School of Pharmacy, Guangdong Medical University, Dongguan 523808, Guangdong, China.
  2. Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang 524023, Guangdong, China.
  3. School of Mathematics, Sun Yat-Sen University, Guangzhou 510275, Guangdong, China.

PMID: 32802121 PMCID: PMC7414372 DOI: 10.1155/2020/2957567

Abstract

MATERIALS AND METHODS: In this study, a network pharmacology-based strategy was used to elucidate the mechanism of GGQLD for the treatment of RVE. Oral bioavailability and drug-likeness were taken as the judgment criteria to search the active ingredients of GGQLD in traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). The affinity between protein and ingredients was further determined using the similarity ensemble approach to find the corresponding targets. According to the genes related to enteritis in GeneCards database, the key targets were screened by intersections between drug and disease targets. And the therapeutic mechanism was predicted using the protein-protein interactions (PPIs), the Gene Ontology (GO), and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, which was verified by detecting calcium ion concentration with the fluorescent probe.

RESULT: 130 active ingredients were screened from GGQLD, including (R)-canadine, moupinamide, formononetin, and other flavonoids. They act on a total of 366 targets, which is mainly distributed in the biological process of hormone binding or signaling pathways of neuroactive ligand receptor interaction, serotonergic synapse, and calcium signaling pathway. Furthermore, serotonin receptors, adrenergic receptors, cholinergic receptors, and dopamine receptors in the enteric nervous system may be the key targets of RVE treatment by GGQLD.

CONCLUSION: This study demonstrated that the potential mechanism that GGQLD can effectively improve the symptoms of RVE may depend on the regulation of calcium ions, serotonin, and gastrointestinal hormone ion that could mutually affect the intestinal nervous system.

Copyright © 2020 Peicheng Zhong et al.

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

  1. Endocr Dev. 2017;32:1-7 - PubMed
  2. BMJ Open Gastroenterol. 2015 Feb 06;1(1):e000011 - PubMed
  3. Dev Biol. 2013 Oct 1;382(1):344-55 - PubMed
  4. Sci STKE. 2005 Feb 15;2005(271):cm1 - PubMed
  5. Sci Rep. 2019 Jul 25;9(1):10822 - PubMed
  6. Yao Xue Xue Bao. 2014 Oct;49(10):1357-64 - PubMed
  7. Chin Med. 2018 Aug 29;13:46 - PubMed
  8. Int J Mol Sci. 2012;13(6):6964-82 - PubMed
  9. Am J Physiol Gastrointest Liver Physiol. 2001 Aug;281(2):G303-10 - PubMed
  10. AAPS J. 2017 Mar;19(2):360-366 - PubMed
  11. Nat Biotechnol. 2007 Feb;25(2):197-206 - PubMed
  12. Nucleic Acids Res. 2018 Mar 16;46(5):2699 - PubMed
  13. Hepatology. 2007 Jan;45(1):42-52 - PubMed
  14. Nat Rev Dis Primers. 2017 Nov 09;3:17083 - PubMed
  15. Nat Chem Biol. 2008 Nov;4(11):682-90 - PubMed
  16. PLoS Pathog. 2011 Jul;7(7):e1002115 - PubMed
  17. Nat Genet. 2000 May;25(1):25-9 - PubMed
  18. J Ethnopharmacol. 2015 Dec 24;176:402-12 - PubMed
  19. Phytomedicine. 2016 Dec 15;23(14):1830-1842 - PubMed
  20. Bioessays. 1998 Aug;20(8):615-26 - PubMed
  21. PLoS One. 2016 Jul 26;11(7):e0159660 - PubMed
  22. Genome Biol. 2014;15(6):122 - PubMed
  23. J Exp Clin Cancer Res. 2018 Aug 28;37(1):201 - PubMed
  24. Bioorg Med Chem. 2010 Nov 1;18(21):7668-74 - PubMed
  25. Mini Rev Med Chem. 2016;16(14):1134-66 - PubMed
  26. Nat Chem Biol. 2013 Apr;9(4):232-40 - PubMed
  27. Curr Protoc Bioinformatics. 2012 Jun;Chapter 1:Unit1.12 - PubMed
  28. Am J Chin Med. 2014;42(1):1-22 - PubMed
  29. mBio. 2010 Nov 30;1(5): - PubMed
  30. Sci Rep. 2017 Mar 03;7:43487 - PubMed
  31. J Cheminform. 2014 Apr 16;6:13 - PubMed
  32. Adv Drug Deliv Rev. 2015 Jun 23;86:2-10 - PubMed
  33. Gut. 2004 Jul;53(7):952-7 - PubMed
  34. Arch Virol. 2015 Jun;160(6):1421-33 - PubMed

Publication Types